Don’t miss out – Fundraiser Event – Cairns’ FIRST screening of the world acclaimed film – Trip of Compassion.
Our previous viewings have sold out within days of being announced. Get your tickets early!
Mind Medicine Australia is thrilled to welcome you to Cairns’ premiere screening of Trip of Compassion, an acclaimed Israeli documentary on MDMA-assisted psychotherapy for the treatment of Post-Traumatic Stress Disorder (PTSD). Trip of Compassion follows a number of patients participating in clinical trials in Israel, and is the first feature documentary to show footage from within psychedelic-assisted therapy sessions.
“I felt like I went through 15 years of psychological therapy in one night.”
– Patient featured in Trip of Compassion
You can watch the preview here:
Following the screening, there will be a Q & A panel. This will be an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.
“Trip of Compassion is the most compelling movie I’ve seen in the last year!”
– Tim Ferris, acclaimed author and podcaster
Director: Gil Karni,
Producers: Zafrir Kochanovsky & Miri Ezra – ttv Productions
Date: Wednesday 20 January 2021
Time: 6:30pm for 7:00pm start – 9:15pm (incl Q&A Panel)
Location: Cairns Central Shopping Centre, Event Cinemas, Cnr Spence & McLeod Streets, Cairns
Ticket Price: $35 General Admission / $25 Concession
More about medicinal MDMA
Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.
Results from Phase 2 clinical trials over the past decade have been so compelling that the Food and Drug Administration (FDA) in the United States recently designated MDMA-assisted psychotherapy as a ‘Breakthrough Therapy’. This designation highlights the FDA’s anticipation that these therapies may offer substantial advantage over current treatments. If forthcoming Phase 3 results confirm these treatments are effective, MDMA-assisted treatment of PTSD may become a prescription medicine as early as 2021 in some jurisdictions.
The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.